XML 47 R38.htm IDEA: XBRL DOCUMENT
v3.23.1

Segment Data - Revenues by Geographic Areas (Detail) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2023 | Mar. 31, 2022
Segment Reporting Information [Line Items] |  |  |  |
Revenues | $ 4,821 | $ 4,750 | $ 9,407 | $ 9,468
Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 2,360 | 2,154 | 4,515 | 4,274
Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,275 | 1,485 | 2,577 | 2,968
Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,186 | 1,111 | 2,315 | 2,225
United States |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 2,733 | 2,669 | 5,462 | 5,372
United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,339 | 1,176 | 2,642 | 2,383
United States | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 581 | 747 | 1,226 | 1,490
United States | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 813 | 746 | 1,595 | 1,498
International |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 2,088 | 2,081 | 3,944 | 4,096
International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,022 | 978 | 1,873 | 1,892
International | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 694 | 738 | 1,351 | 1,478
International | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 373 | 364 | 720 | 727
Medication Delivery Solutions | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,070 | 1,049 | 2,109 | 2,146
Medication Delivery Solutions | United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 616 | 590 | 1,235 | 1,210
Medication Delivery Solutions | International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 454 | 460 | 873 | 936
Medication Management Solutions | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 723 | 604 | 1,430 | 1,231
Medication Management Solutions | United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 550 | 461 | 1,114 | 945
Medication Management Solutions | International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 173 | 143 | 316 | 286
Pharmaceutical Systems | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 567 | 501 | 976 | 897
Pharmaceutical Systems | United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 173 | 125 | 292 | 228
Pharmaceutical Systems | International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 394 | 375 | 684 | 669
Integrated Diagnostic Solutions | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 888 | 1,150 | 1,841 | 2,295
Integrated Diagnostic Solutions | United States | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 422 | 618 | 930 | 1,232
Integrated Diagnostic Solutions | International | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 466 | 532 | 911 | 1,062
Biosciences | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 386 | 335 | 736 | 674
Biosciences | United States | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 159 | 129 | 296 | 258
Biosciences | International | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 228 | 206 | 440 | 416
Surgery | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 381 | 340 | 744 | 701
Surgery | United States | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 295 | 268 | 582 | 549
Surgery | International | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 86 | 72 | 162 | 152
Peripheral Intervention | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 468 | 450 | 902 | 863
Peripheral Intervention | United States | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 256 | 240 | 492 | 457
Peripheral Intervention | International | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 213 | 210 | 410 | 407
Urology and Critical Care | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 336 | 320 | 670 | 661
Urology and Critical Care | United States | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 263 | 239 | 522 | 492
Urology and Critical Care | International | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | $ 74 | $ 82 | $ 148 | $ 168

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_MedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_LifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_InterventionalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_MedicationDeliverySolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_MedicationManagementSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_PharmaceuticalSystemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_IntegratedDiagnosticSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_BiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_PeripheralInterventionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_UrologyandCriticalCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |